Correspondence

ACMD advice on the classification and schedule of Remimazolam

Report from the Advisory Council on the Misuse of Drugs (ACMD) on the classification and schedule of Remimazolam.

• From: Home Office and Advisory Council on the Misuse of Drugs
• Published: 2 December 2022

This was published under the 2022 to 2024 Sunak Conservative government

Documents

ACMD advice on the classification and schedule of Remimazolam

HTML

ACMD advice on the classification and schedule of Remimazolam

PDF, 115 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The ACMD is grateful to the Medicines and Healthcare products Regulatory Agency (MHRA) for providing a written dossier and oral presentation on the ultra-short-acting Benzodiazepine Remimazolam (Byfavo).

Further to these representations, the ACMD is able to provide advice regarding the appropriate classification and schedule for this medicine.

Published 2 December 2022